GenBody completes Geochang BR Center construction: completion of vertical integration of bio materials

Geochang BR Center leaps forward as a hub for cutting-edge bio research and production

THE BIO | 성재준 기자 | sjj@thebionews.net | 2024.06.25 14:55

GenBody unveiled on June 24 the completion of the Geochang BR (Bio Resource) Center, marking the full integration of research, development, and production of bio resources and diagnostics.

According to the company, the completion of the Geochang BR Center is expected to strengthen global competitiveness and support local economic growth through job creation.

Geochang BR Center is equipped with cutting-edge facilities and technology and is expected to conduct research, development, and production of various bio- and diagnostic resources. It will prioritize projects such as infectious disease diagnostic technology and customized raw material research, aiming to establish GenBody as a leader in the global biomarket.

Prior to the completion ceremony, GenBody held a business agreement ceremony with Japan’s ‘KIWA Laboratory Animals (hereinafter referred to as KIWA)’ to ensure the successful establishment of the Geochang BR Center. Established in 1978, KIWA not only supplies laboratory animals and related equipment but also produces world-class antibodies. Through this partnership, both companies aim to strengthen joint research efforts and technology exchange.

Since its establishment in 2012, GenBody has concentrated on developing bio-source technology essential for commercializing rapid immune diagnostic kits. The company has also been at the forefront of securing high-quality antigen and antibody manufacturing technology, crucial as core raw materials, alongside advanced technology for commercializing high-performance diagnostic kits. In addition, GenBody has engineered its proprietary analysis equipment (Reader), designed to provide objective analysis of diagnostic kit results.

“The completion of the Geochang BR Center marks a significant milestone for our company, signaling a new era of advancement,” said Jeong Jeom Gyu, CEO of GenBody. “Through this facility, we aim to further strengthen our global competitiveness and contribute to public health and environmental sustainability by delivering bio- and diagnostic solutions.”